Abstract. Gynecological malignancies are a leading cause of mortality in the female population. The present study intended to identify the association between three severe types of gynecological cancer, specifically ovarian cancer, cervical cancer and endometrial cancer, and to identify the connective driver genes, microRNAs (miRNAs) and biological processes associated with these types of gynecological cancer. In the present study, individual driver genes for each type of cancer were identified using integrated analysis of multiple microarray data. Gene Ontology (GO) has been used widely in functional annotation and enrichment analysis. In the present study, GO enrichment analysis revealed a number of common biological processes involved in gynecological cancer, including 'cell cycle' and 'regulation of macromolecule metabolism'. Kyoto Encyclopedia of Genes and Genomes pathway analysis is a resource for understanding the high-level functions and utilities of a biological system from molecular-level information. In the present study, the most common pathway was 'cell cycle'. A protein-protein interaction network was constructed to identify a hub of connective genes, including minichromosome maintenance complex component 2 (MCM2), matrix metalloproteinase 2 (MMP2), collagen type I α1 chain (COL1A1) and Jun proto-oncogene AP-1 transcription factor subunit (JUN). Survival analysis revealed that the expression of MCM2, MMP2, COL1A1 and JUN was associated with the prognosis of the aforementioned gynecological cancer types. By constructing an miRNA-driver gene network, let-7 targeted the majority of the driver genes. In conclusion, the present study demonstrated a connection model across three types of gynecological cancer, which was useful in identifying potential diagnostic markers and novel therapeutic targets, in addition to in aiding the prediction of the development of cancer as it progresses.
Introduction
Gynecological malignancies, particularly ovarian cancer, cervical cancer and endometrial cancer, are serious medical conditions in women and have been leading causes of cancer mortality in recent years. However, the use of cancer markers for early and progressive detection remain lacking (1) . In addition, research has demonstrated that there are close associations across the three aforementioned types of cancer. It has been demonstrated that the progress and the development of the three aforementioned types of cancer are similar, which may be useful when diagnosing any one of these three cancer types. In the case of endometrial cancer, prior to the development of endometrial carcinoma, the endometrium undergoes progressive neoplastic alterations in a parallel fashion to the premalignant alterations observed in the cervix prior to the development of cervical carcinoma (2) . The rationale of oophorectomy in surgical management is that endometrial cancer may metastasize to the ovary, in which women with endometrial cancer are at risk for synchronous and metachronous ovarian cancer, and the source of estrogen may be eliminated by oophorectomy (3, 4) . In cancer cells, oncogenic transformation is associated with major alterations in gene expression (5) . With the advent of large-scale screening of cancer genomes, hundreds of genes with alterations in different types of tumors from patients with cancer have been identified (6) (7) (8) (9) (10) , which revealed that cancer is a complex disease caused by genetic alterations in multiple genes (11, 12) . In order to elucidate the cancer marker genes and biological processes associated with each type of gynecological tumor, and the potential underlying mechanism of associations among gynecological tumors, the contribution of identified differentially expressed genes (DEGs) to the pathogenesis of gynecological tumors must be understood.
To analyze different DEGs, high-throughput experimental methods, including microarray analysis, have been widely used in a number of studies (13, 14) . A vast quantity of microarray data has been produced and deposited in publicly-available data repositories, including the Gene Expression Omnibus (GEO) (15) . With the methods of integrated bioinformatics analysis, researchers have been able to advance the identification of genetic signatures. This may provide insights into the underlying biological mechanisms of the development of gynecological tumors.
Chung et al (16) revealed that microRNA (miRNA)-200b/a is a direct transcriptional target of grainyhead like transcription factor 2, which is associated with development and overall survival in epithelial ovarian cancer. Halabi et al (17) demonstrated that 41 genes, including matrix metalloproteinase (MMP)7 and tumor protein 53, were involved in the potential underlying mechanisms of ovarian cancer. Espinosa et al (18) revealed that six genes encoding cyclin B2, cell-division cycle protein 20, protein regulator of cytokinesis 1, synaptonemal complex protein 2, nucleolar and spindle associated protein 1 and cyclin-dependent kinase inhibitor 2 belonging to the mitosis pathway, were potential markers for screening or therapeutic targets of cervical cancer. However, biomarkers which were identified in this way have had poor translation into actual clinical practices. Results have been non-concordant among studies due to small sample sizes. In addition, the studies into the associations of biomarker genes (driver genes) remain lacking among the different types of gynecological tumors.
A robust driver gene biomarker signature may be beneficial for the diagnosis and targeted treatment of gynecological tumors. In the present study, in order to identify a driver gene biomarker signature for the three types of gynecological tumors, data from the Metabolic Gene Rapid Visualizer database (MERAV, which is derived from GEO) was used (19) . In MERAV, microarrays were normalized together to eliminate systematic errors caused by different batch experiments.
The present study devised a target network for ovarian cancer, cervical cancer and endometrial cancer using the selected driver genes, and further investigated the identified DEGs via functional enrichment analysis, pathway enrichment analysis and protein-protein interaction (PPI) networks. In addition, the present study extracted clinical information of ovarian cancer, cervical cancer and endometrial cancer from The Cancer Genome Atlas (TCGA) data portal. Subsequently, driver genes in each type of cancer were analyzed. It was important to investigate the underlying mechanism of each gynecological tumor and whether the identified driver genes contributed to these diseases. Subsequently, a network was generated between the miRNAs and the identified driver genes, using the method of mining the Mir2 disease and Tarbase databases which provide information on miRNAs, diseases and the interactions between miRNAs and genes. Finally, the present study determined hub-genes and hub-miRNAs across the gynecological tumors to study the potential underlying mechanisms of the developments of gynecological tumors, which may shed light on different strategies for the design of biological targets for cancer therapies.
Materials and methods

Identification of gene expression datasets.
In the present study, DEGs were identified between normal tissues and tumors extracted from the MERAV database from the National Center for Biotechnology Information GEO database (MERAV, http://merav.wi.mit.edu). The experimental samples for the present study are presented in Tables I and II. The following information was extracted from each identified study: GEO accession number, sample type, number of cases and controls, and gene expression data. Studies in which the microarray data were uncertain were excluded. The experimental protocol for the present study is presented in Fig. 1 .
Integrated analysis of DEGs identified in the extracted databases. Information was extracted from the microarray datasets in MERAV which are presented in Tables I and II, respectively. Following the intersection of the microarray datasets, the DEGs were established between the normal and cancer tissues. In the present study, the degree of differential gene expression was measured by fold-change based on the Student's t-test. A fold-change value >2 or <0.5 and t-test P<0.01 for a gene was considered to be significant. The differential expression analysis was conducted using the Linear Models for Microarray Data package in R (20) .
Protein interaction network. The DEGs were subsequently applied to the Human Protein Reference Database (21) (HPRD, www.hprd.org), to identify the more complex functional interactive driver genes of separate cancer types. Genes with interactions with each other were extracted from the DEGs as mentioned above (presented in Tables III-X). The PPI network is a useful research tool for investigating the cellular networks of protein interactions, and was downloaded from the HPRD. Cancer-associated gene-gene interaction networks were constructed by mapping the DEGs into the HPRD PPI network for each cancer (cervix tumor, ovarian tumor and endometrium tumor). To make it easier to identify the driver genes, the present study calculated the lines attached to each node, which was defined as the degree of the node. The nodes that exhibited degrees ≥4 were defined as driver genes. The nodes whose degree was ≥4 were considered to serve more complex roles in the development of the diseases of interest. These nodes were then extracted for the PPI network (Fig. 2) . The present study constructed a connected network which contained the driver genes across the three cancer types. Through this method, it was determined whether the driver genes of the separate cancer types had any interaction with each other. The networks were constructed using Cytoscape version 3.3.0 (www.cytoscape.org).
miRNAs regulating gene network construction. The present study analyzed the association between miRNAs and the identified driver genes (Fig. 3) . This process was performed by extracting a list of miRNAs which were associated with the type of cancer (cervical tumor, ovarian tumor or endometrial tumor) from the Mir2 Disease database (www. mir2disease.org) (22) . Following this step, a network was created regarding the regulatory associations between the miRNA and the specific driver gene of each type of cancer in order to identify the hub-miRNAs of the gynecological tumors. The associations of the regulation were extracted from Tarbase (diana.cslab.ece.ntua.gr/tarbase) (23) .
Functional and pathway enrichment analysis. In order to assess the functional relevance of the aforementioned DEGs, a pathway analysis was created based on the Database for Annotation, Visualization and Integrated Discovery (DAVID) (24) . DAVID provides a useful tool to analyze large gene lists, including gene ontology (GO) and pathway analysis. DEGs in different diseases were applied to this database in order to detect potentially represented functions. GO-categories were organized based on the GO database (25) (www. geneontology.org). In addition, pathway analysis was based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (26) (genome.jp/kegg). Significant categories were identified by expression analysis systematic explorer scores, a modified Fisher's exact P-value. The threshold for significance for a category was considered to be P<0.01, with >4 genes for the corresponding term.
Survival analysis. The present study used TCGA database to extract clinical information and gene expression profile information. At the start of the analysis, the expression values of each driver gene were listed, which were identified via the PPI network. To find the median level of gene expression, the samples were divided into two groups by median of expression (high expression group and low expression group). Additionally, the corresponding clinical information of each sample was extracted. Survival data representing time between initial diagnosis and mortality were downloaded directly from TCGA data portal (tcga-data.nci.nih.gov/tcga/tcgaHome2. jsp) (27) . With this information, the present study was able to estimate the association between the identified driver genes of the three types of cancer mentioned above and the survival rates of patients. All analyses were conducted using custom-written code in R (www.r-project.org).
Results
Integrated analysis of multiple studies to establish the driver genes in cancer.
There are multiple genes that contribute to Table I . Datasets from the Metabolic Gene Rapid Visualizer database (cervix).
Tissue type Datasets
Normal, n=4 GSM176135, GSM175833, GSM176130, GSM176140
Tumor Squamous cell carcinoma, n=5 GSM152635, GSM277702, GSM46919, GSM102527, GSM152587 Squamous cell carcinoma non-keratinizing, n=5 GSM179907, GSM46942, GSM76614, GSM152580, GSM203742 Squamous cell carcinoma keratinizing, n=3 GSM117576, GSM152723, GSM152751
Adenoma, n=6 GSM179956, GSM152667, GSM152719, GSM179853, GSM325835, GSM203622 Table II . Datasets from the Metabolic Gene Rapid Visualizer database (ovary and endometrium).
Ovary, n=4 Endometrium, n=22
Normal tissues GSM175789 GSM175777, GSM175778,  GSM176131  GSM175779, GSM175780,  GSM176136  GSM175781, GSM175783,  GSM176318  GSM175784, GSM175785,  GSM176039, GSM176040,  GSM176041, GSM176043,  GSM176093, GSM176099,  GSM176127, GSM176137,  GSM176141, GSM176142,  GSM176144, GSM176146,  GSM176143, GSM176145,   Tissue type  Ovary serous adenocarcinoma, n=11  Endometrioid carcinoma, n=12   Tumors  GSM8897, GSM203626, GSM15267,  GSM102425, GSM117582,  GSM102445, GSM46831, GSM152577,  GSM117586, GSM117590,  GSM88973, GSM152581, GSM27769,  GSM88952, GSM88966,  GSM277737, GSM301703 GSM102469, GSM102492, GSM53058, GSM88978, GSM46923, GSM46937 Figure 1 . Experimental protocol of the present study. DEG, differentially express genes; GO, gene ontology; MERAV, Metabolic Gene Rapid Visualizer database; TGCA, The Cancer Genome Atlas. Gene   RB1  HTRA1  MTOR  CLDN5  NARF  PURA  MCM7  KPNA2  PLSCR4  CYBA  NCAPD2  RBM8A  MCM2  LMNB1  PRKD1  DCUN1D1  NCF4  RECK  PLK1  MEIS1  PSMA5  DDAH2  NME4  REV3L  AR  NCOA1  PSMB10  DMPK  NPLOC4  RFC3  PPP1CA  PBX1  PSMB9  EPS8  NR2F1  RNF126  ABL1  PIAS3  PSMD2  EXOSC5  NR2F2  RPA3  LMNA  POLA2  RACGAP1  GABBR1  NRAS  RRM1  PTN  PPP1R14A  RTN3  GAS6  NTF3  RRM2  TRIP13  AXL  SNRPB  GCH1  NTRK2  SAT2  CAV1  BUB1B  TOR1AIP1  GCHFR  NUB1  SDC2  CDC20  CCL14  TUBA4A  GLRX3  NUP210  SEC24A  CDC6  CCR5  UBTF  GMFB  NUP50  SELENBP1  FLNA  COL4A5  USP6NL  GOLGA2  PAFAH1B3  SERBP1  FXR2  CSNK1D  UTP3  HOXD13  PAK2  SH3BP5  ZHX1  DBF4  ACTN4  ILK  PAM  SMC4  CCNA2  DVL3  ADAM10  KANK1  PCGF2  SNRPD1  DGKZ  EFEMP2  ANTXR2  LAPTM5  PHACTR4  SNTB2  MCM10  EIF4EBP1  ARHGAP17  LDB2  PLK2  SNX27  MCM6  EZH2  ASPM  LDOC1  PNO1  SPIN1  PCNA  FAM46A  BID  LMO4  PNP  SSSCA1  RBPMS  HOXD10  BMP4  LRP1  PPIA  STXBP2  RPS6KA1  HSPA4  BNIP2  LRP6  PPIH  SUB1  SAT1  ITGB3BP  C1QA  LRRC41  PRPF18  TALDO1  BUB1  KLF6  CBX4  LZTS2  PSMA6  TGFBR3  CSNK1E  MAD2L2  CCNE1  MAGEH1  PSMB7  TNFRSF1A  DCN  MAP2K4  CCR1  MELK  PSMD4  UFD1L  FGFR1  MAPK10  CDC42BPA  MPDZ  PSME3  WSB2  FXYD1  MCM5  CENPE  MTA1  PSMF1  XPNPEP1  GMNN  MITF  CHFR  MYCBP  PSTPIP1  YLPM1  HOXA10  MMP9  CIB1  MYL9  PTTG1  ZMIZ1 the cause of the aforementioned cancer types and, therefore, no single gene is a determining factor in diagnosis. It was identified that each type of cancer was driven by different variations of genes that serve key roles during the development of pathology. However, no single gene may explain the heterogeneity of each type of cancer. In the case of cervical cancer, 186 genes in squamous cell carcinoma of the cervix (Table III) , 107 genes in keratinized squamous cell carcinoma of the cervix (Table IV) , 96 genes in cervical adenocarcinoma Grade 3 (Table V) , 133 genes in non-keratinized squamous cell carcinoma of the cervix (Table VI) and 203 genes in cervical adenocarcinoma Grade 2 (Table VII) were identified to be important. In addition, 120 genes and 76 genes were established, respectively, in adenocarcinoma of the ovary Grade 2 Gene   FYN  ADAM10  ARHGAP17  HSPB2  PHF1  TMOD1  ZHX1  ADAM17  ARMCX2  ID4  PIK3C2B  TMSB10  ABL1  ANXA6  BIN1  LDB2  PIP5K1C  TPD52  BCL2L1  AXL  CBX3  LDOC1  PNP  UBTF  FXR2  BCL11A  CLDN5  LMO4  PSME3  ZHX2  TBP  CSNK1E  CNN3  LRP1  PSMF1  ZMIZ1  AR  DMPK  CNNM3  LRP6  PTOV1  ZNF76  BARD1  ITGB3BP  CNTNAP1  LSM5  PTPN12  BID  KPNA6  CRYAB  MAGI2  RAE1  DDX24  MAD2L2  CSE1L  MAPK10  REV3L  NCOA1  MCL1  CSTF1  MIS12  RUNX1T1  PDGFRB  NR2F1  EFEMP2  MPDZ  SDC2  PRKD1  NTRK2  EXOSC5  MTA1  SFRP1  PSEN1  PPP1R14A  FGFR1  MYCBP  SH3BP5  RBPMS  PTN  FXYD1  NPDC1  TAF9  SPTAN1  RTN3  FZD6  NR2F2  TCF7L2  TCF4  SYK  GAS6  NTF3  TERF1  TGFA  VIM  GDI1  NUDT21  TFDP1  A2M  ANTXR2  GTF3C3  PBX1  TGFBR3  ACP1  AQP1  HOXA10  PDGFD  TLN2   Table V . Driver genes identified by integrated analysis of the microarray datasets (cervical adenocarcinoma G3). AR  BAD  PLD2  CIB1  MAPK10  SERPINA1  CAV1  BAHD1  PPA1  CLDN5  MED14  SF1  FLNA  C1QBP  PRKD1  CUL4B  MPDZ  SMO  PPP1CA  CPSF6  SAT1  DMPK  MYL9  SPINT2  NCK2  CSNK1D  SMAD1  EFNB1  NR2F1  SSBP3  PLSCR1  DOCK1  SNAP23  F3  NTF3  SSR1  SUMO4  DVL2  TAF1D  GDI1  PCGF2  STAM  LMNA  FXR2  TAF9  HOXA10  PDPK1  SYNE1  LRP1  FXYD1  TCF4  HOXD10  PHACTR4  TCF7L2  PSEN1  ILK  WIPI1  HOXD13  PHYHIP  TGFBR3  PTN  LDB1  ACVR2A  HSPA1B  PLSCR4  TMF1  CSNK1E  LMO4  ANTXR2  HSPBAP1  PNPLA2  UBTF  DVL3  MAP2K4  ATG12  KANK1  PPP1R10  VAMP8  MMP14  NCOA1  CD82  KPNA6  PTCH2  WASF1  PPP1R14A  NTRK2  CDC42BPA  LDB2  RNF138  WASF2  ALDOA  PBX1  CDC42EP1  LRP6  RUNX1T1  ZHX1 and Grade 3 (Tables VIII and IX) . A total of 168 genes were established in endometrial carcinoma (Table X) .
Gene
Integrated PPI (protein-protein interactions) network construction. Based on the HPRD, the interaction network of the identified driver genes was constructed, which consisted of 101 nodes (genes that form associations) and 185 edges (biological association) (Fig. 2) . Genes with a higher degree of association (degree ≥4) were observed to be larger in size, and included the genes CDK1, CAV1, ZBTB16, Jun proto-oncogene AP-1 transcription factor subunit (JUN), RAF1, RB1, minichromosome maintenance complex component 2 (MCM2), AR, ABL1, LMNA, FLNA, DCN, FYN, SMAD1, LRP1, PSEN1, EP300, CTNNB1, collagen type I α1 chain (COL1A1) and FOS. Through this method, it was identified that driver genes in each gynecological cancer have contact interactions.
Comprehensive analysis of miRNA regulation and the selected driver genes. Fig. 3 illustrates that certain miRNAs serve important roles in regulating the driver genes. In the present study, it was demonstrated that a number of miRNAs regulate separate networks [for example the let7 family, miRNA (miR)-23b, miR-21, miR-214 and miR-218]. miRNAs that were confirmed to be significant in cervical cancer, including let7c and let7b, are also found to be associated with the other two cancers in this study. This information may be important in establishing the connections between the three gynecological cancer types, which may be used in the development of targets for further research and diagnosis.
Functional and pathway enrichment analysis. GO analysis revealed that the identified genes of cervical tumors, ovarian tumors and endometrial tumors were predominantly involved in the illustrated biological processes (Fig. 4) . The top three significant biological processes of cervical cancer were 'mitotic cell cycle', 'cell cycle' and 'cell cycle process', while for ovarian cancer, the biological processes consisted of 'cell cycle process', 'cell cycle phase' and 'macromolecule metabolic process'. For the progression of endometrial cancer, the top three biological processes observed to be at fault for cancer progression were 'response to organic substance', 'regulation of cell proliferation' and 'skeletal system development'. Using the method of pathway analysis, it was revealed that genes in cervical cancer were significantly enriched in 'cell cycle', 'pathways in cancer' and 'DNA replication'. Ovarian cancer was observed to be significantly enriched in 'MAPK signaling pathway', 'cell cycle' and 'oocyte maturation'. Endometrial cancer was observed to be significantly enriched in 'pathways in cancer', 'focal adhesion' and 'complement and coagulation cascades' (Fig. 5) . Fig. 6 illustrates the association between survival time and survival rate in the high and low expression groups. The genes MCM2, Table VI . Driver genes identified by integrated analysis of the microarray datasets (cervical non-keratinized squamous cell carcinoma). AR  FXR2  FOXO1  TLR2  FBN2  NTF3  ABL1  ILK  GMNN  TXNDC9  FGR  NTRK2  CAV1  LMNA  HOXD10  XRCC4  FXYD1  NUBP1  CHD3  MEIS1  ICAM3  YAP1  GDI1  PALLD  HIF1A  NCOA1  ITGB2  ADCY6  HCLS1  PDPK1  PTPN6  PAG1  LCP2  ADI1  HLA-DMB  PGK1  SAT1  PBX1  LRP1  AGTPBP1  HLA-DRA  PGLS  FLNA  PIAS1  MAFG  ANTXR2  HOXD13  PIK3R3  HOXA10  PSEN1  MPDZ  ANXA6  HSPB2  PLTP  PLSCR1  PTN  NDN  ARHGDIB  LCP1  PNP  RAF1  WASF2  NR2F2  CDC37  LDOC1  PRRX1  DCN  ZHX1  PAICS  CITED2  LILRB2  RAB11FIP2  EZR  ACTR3  PLSCR4  CLDN5  LRP6  RAB18  MMP14  BIN1  PPP1R14A  CNN3  MAPK10  RFXANK  PDGFRB  C1QB  PPP2R1A  COL4A5  MED14  RUNX1T1  ABCA1  C1QC  PRDX2  DOCK1  MTA1  SAT2  C1QA  CSNK1D  SNTB2  DVL2  MYO5B  SEPHS1  CSNK1E  DGKZ  SSSCA1  ENO1  NARF  SF1  DMPK  DVL3  TCF4  FAM46A  NISCH  ELN  EFEMP2  TLR1  FBLN1  TICAM1  SNX2  SYNE1  TCF7L2  VTA1  TRAP1  TMEM8B  TMOD1  TMSB10  TPD52  SH3BP5  WASF3  ZNF76  TEAD3  TIMP2  NR2F1 MMP2, COL1A1 and JUN are presented in the figure, and it was observed that the driver genes of the expression groups were able to divide each of the target cancer types into two groups, one of which contained the high expression group with the other containing the low expression group. Therefore, in order to determine whether the driver genes had a key role in the development of gynecological tumors and the connective function of separate cancer types, the present study aimed to identify the association between the target cancer driver genes and other types of gynecological cancer.
Survival analysis of patients with gynecological tumor.
Gene
Discussion
The principal challenge of high-throughput cancer genomics is to identify specific driver genes and the underlying mechanisms of carcinogenesis, apart from the vast quantity of heterogeneous genomic alteration data. Numerous studies have focused on identifying individual functional modules or pathways involved in cancer (28) (29) (30) . Based on this methodology, the analysis of the present study focused specifically on DEGs in order to reveal the transcriptional responses of gynecological tumors. The results of this analysis suggested that the common biological processes of cancer of the cervix, ovary and endometrium were those involved in the cell cycle and the regulation of macromolecule metabolism. The cell cycle is the progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication. Research has shown that interference with cell cycle components may Table VII . Driver genes identified by integrated analysis of the microarray datasets (cervical adenocarcinoma G2). ABL1  HSPA5  ASAP1  PSMF1  ASS1  EHD2  AR  HTRA1  AXL  QKI  ATRX  ENAH  CAV1  LMNA  BCR  RAB4A  AURKA  ENO1  PPP1CA  MEIS1  BGN  RNF138  AURKB  ERBB3  FLNA  NTRK2  BMP4  SDC2  BIN1  FBLN1  FYN  PRNP  BRCA2  SMARCE1  BIRC5  GAS6  MMP2  PTPN12  CDKN2A  SNAP29  CAPZB  GLRX3  SMAD1  SMAD5  CSNK1E  TAF7  CAV2  GOLGA2  NCK2  TAF9  DMPK  TCF4  CBX4  GTF2I  RB1  TTF2  DOCK1  TGFBR3  CD81  HAT1  PTN  DVL2  DR1  THBS2  CDT1  HOXD10  PTPN6  EFEMP2  FGFR1  TIFA  CEP76  HSPA1B  SMAD7  FXR2  FXYD1  TIMP2  CLDN5  HSPB2  SUMO4  HOXA10  GDF5  TNFRSF1A  CLU  IDE  A2M  HOXD13  GNA12  ZHX1  CNN3  IFI35  AP1M1  LRP1  KIDINS220  ADI1  CNTNAP1  IFNAR1  CDC5L  NCOA1  LDOC1  AHNAK  COL4A5  ILK  EZR  NOTCH2  LRP6  ALDOA  COL6A3  IQGAP1  MMP14  PBX1  MAFG  ANTXR1  COX5A  JAG1  PIAS1  PDGFRB  MAP2K4  ANTXR2  CUL4B  KANK1  CD2AP  PRKD1  MAPK10  ANXA6  CXCL12  KDM2A  CDH1  SAT1  MEF2C  AQP1  DCLRE1A  KPNA6  DCN  WASF2  POLE3  ARHGAP17  DDX24  LCAT  DRAP1  YAP1  PPP1R14A  ARHGEF6  EFNB1  MAD2L1BP  ELN  ACVR2A  PRRX1  ASH1L  EFS  MAP3K3  MCM4  NR2F2  PLSCR4  RUNX1T1  SYNE1  WNK1  MED14  NTF3  PPA1  SALL2  TEAD3  YLPM1  MPDZ  NUDT21  PPP1R10  SAT2  TERF1  ZMIZ1  MSN  PALB2  PPP2R1A  SETD7  THBS3  MYCBP2  PALLD  PSMB10  SH3BP5  TMEM8B  MYO5B  PBX3  PURA  SH3KBP1  TSPAN4  NFE2L1  PDGFD  RAB11FIP1  SKAP1  TWIST2  NMI  PHACTR4  RAB11FIP2  SPARCL1  UBTF  NPHS2  PIP4K2B  RBPJ  STX3  VGLL4  NR2F1  PKD2  REPS2  STX7  WFDC2 lead to tumor formation (31) . Certain cell cycle inhibitors, including retinoblastoma protein and tumor protein 53 may mutate during replication, causing the cell to proliferate uncontrollably, ultimately resulting in a tumor. Furthermore, the proportion of active cell division in tumors is much higher compared with the rate in normal tissue.
Gene
To clarify the hub genes in ovarian cancer, cervical cancer and endometrial cancer, DEGs were predicted to be biomarkers for each cancer using PPI networks. It is considered that hub nodes are genes that are highly connected with other genes and have been predicted to serve key roles in numerous networks. In addition, highly connected hub genes were proposed to have a considerable role in biological development. Hub nodes have more complex interactions compared with those of other nodes, which indicates that they have pivotal roles in the underlying mechanisms of disease. In addition, certain identified biomarkers of each type of cancer were extracted from each network and these driver genes were placed into one PPI Table IX . Driver genes identified by integrated analysis of the microarray datasets (adenocarcinoma of the ovary Grade 3).
CDK1
HLA -DRA  CD14  FCGR2B  PDGFD  NR2F2  AURKB  ICAM3  CDC20  FOS  SLPI  CAV1  KRT7  CDH1  GCA  SMC4  PTPN6  MAD2L1  CDKN2A  GNE  SOX9  ZBTB16  MAL2  CEBPG  GPRASP1  SPINT1  BCL2L1  MAP3K5  CENPA  HLA-DMB  ST14  HSPA1A  PDGFRA  CKS2  HLA-DRB1  STRBP  IRS1  PDGFRB  CLDN1  LAPTM5  TACC1  ITGB2  PMAIP1  CLDN3  LCP1  TOP2A  MCM2  RACGAP1  CRIP1  LRP1  TRIP13  NDC80  RBPMS  CTSS  MSLN  TYROBP  SYK  TPD52  CXCR4  MUC1  ZWINT  TPD52L1  ALOX5  DBF4  MUC16  ECT2  BCL11A  ALOX5AP  DSC2  NCAPD2  CCNB1  CCNB2  BIK  DSG2  NR2F1  ERBB3   Table VIII . Driver genes identified by integrated analysis of the microarray datasets (adenocarcinoma of the ovary Grade 2). JUN  MEF2C  HSPA1A  CNNM3  GNE  PHF1  FXR2  NCOA2  HTRA1  COX5A  GNG4  PKD2  RAF1  NIF3L1  IKZF4  CRY2  GPRASP1  PLA2G16  RBPMS  PCBD1  LIFR  CTF1  HMGA1  PLK1  ZBTB16  PDGFRA  MAPK10  CTSD  HSPA2  PTPN13  PRKACA  PRTFDC1  MYO15A  DCN  ICAM3  RBBP8  CAV1  STAT5A  NFE2L1  DST  IGFBP4  RBP1  MAP3K3  APBB1  NR2F6  ELF3  IRS1  SDC2  MAP3K5  C1R  PER1  ELK1  KIAA1217  SGK1  NCOA1  C1S  PTPN6  ENAH  MAFG  SH3BP5  PDGFRB  CALCOCO2  SERPING1  ENG  MRAS  SMC3  SIN3A  CD2AP  SIN3B  EPS8  NBL1  SNCA  ABLIM1  DCTN1  TGFBR3  ETV6  NFATC4  SNRNP70  DDX17  DMPK  TSC22D3  EYA2  NINL  SPOP  FEZ1  DVL2  UBQLN1  FLAD1  NR2F2  SPTBN1  GATA4  FHL2  ACTA2  FOXO1  OLFML3  SPTBN2  GOLGA2  FLNA  BEGAIN  FOXO3  PAICS  ST13  LRP1  FXYD1  CCT5  FTH1  PDGFD  STRBP  TCF4  THRA  TPM2  TXN  USP13  ZC3H10  TEAD1  TOP2A  TRIM21  TXNDC9  WTIP  ZFPM2 Table X . Driver genes identified by the integrated analysis of the microarray datasets (endometrial carcinoma). EP300  CDKN2A  F2R  AMFR  EPN3  MMP11  JUN  COL3A1  FZD5  AXL  EPR1  MMP26  CAV1  EGR1  HLA-DMB  BCL11A  FOSB  MYO5B  CTNNB1  ERBB4  HOXA10  BCL2A1  GALNT10  NRG2  ABL1  FBLN1  ID1  BIK  GAS6  NRXN2  AR  FBN1  ID4  BLNK  GATA2  PCOLCE  TCF4  FLNA  IDE  C1R  GCH1  PDGFRB  THBS1  FOXO1  INADL  C1S  GCHFR  PKD2  TUBA4A  HLA-DRA  JUND  C3AR1  GPI  PNP  ATXN1  ID3  LMO4  CCND2  GPRASP1  PPP1R14A  COL1A1  IGFBP5  LNX1  CDH11  HLA-DQB1  PRDM1  DCN  LAMB3  NCALD  CDKN1A  HLA-DRB1  PSTPIP2  LRP1  MITF  NCF2  CDKN2C  HLF  PTGDS  C3  MYC  NR2F2  CFB  HOXA9  PTGS2  COL7A1  PLAT  PDGFRA  CGN  ID2  R3HDM2  FBLN2  RUNX1T1  PLEKHF2  CLEC3B  IGFBP4  RAB25  FOS  S100A8  PTPN13  CLK1  IGFBP6  RAB3IP  GNAI2  SERPINA1  RAB8B  CXADR  IL33  RAPGEF6  IGF1  SYK  RABAC1  CXCL10  IRS1  S100A9  LAMC2  TGFB1I1  ROR2  DNM1  KLF5  SCRIB  MUC1  CD14  SFN  DPYSL2  LAPTM5  SEC24D  NID1  COL5A1  SFRP1  ECM1  LDB2  SNTB2  PRKD1  CRMP1  TFAP2A  EDNRA  LUC7L3  SOX9  PTPN12  DBP  TJP2  EFEMP2  MAFB  SPINT1  VCAN  DDR2  TRPC1  EFS  MAL2  SPP1  CD74  F10  WNT5A  ENO2  MAPK10  ST14  SYTL1  TJP3  TLR3  TRO  WASF2  WNT4  TBL1X  TLR2  TPD52  USP54 WNT2 ZEB1 Figure 2 . Protein-protein interaction networks of the DEGs identified by integrated analysis of the microarray databases throughout cancer of the cervix, ovary or endometrium. Each cancer holds a number of DEGs. Driver genes were extracted from the DEGs, whose degree (the number of lines attached to each node) was ≥4. The orange dots represent cervical carcinoma, green dots represent ovarian carcinoma and blue dots represent endometrial carcinoma. Genes with a higher degree of association exhibit a larger node size. Each biological association (an edge) between two genes (nodes) was supported by at least one reference from the literature or information stored in the Human Protein Reference Database. DEGS, differentially expressed genes.
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network with the duplication hub genes eliminated. Therefore, the particular hub genes of each gynecological cancer and the connection nodes across the three types of cancers may be identified. Accordingly, the identification of hub genes and hub connected genes involved in each gynecological cancer may lead to the discovery of the association across ovarian cancer, cervical cancer and endometrial cancer, and may lead to the development of effective diagnostic and therapeutic approaches.
In order to ascertain a causal association across the three types of gynecological cancer, the present study extracted clinical information and gene expression profile information from TCGA database, and used the hub connected genes identified in the PPI network to perform survival analysis. In the present study, four noteworthy genes were identified, including MCM2, MMP2, COL1A1 and JUN.
The present study demonstrated that MCM2 may serve a key role in cervical cancer. A poor prognosis was associated with lower expression. Furthermore, MCM2 was highly connected with ovarian cancer and endometrial cancer. The results suggested that MCM2 is a component of the DNA replication licensing complex, with a rich binding surface that directs multiple regulatory interactions of cancer significance, marking DNA replication origins during the G1 phase of the cell cycle for use in the subsequent S-phase. A deficiency of MCM2 results in death or morbidity in the absence of an overt tumor (32) . These processes of DNA replication have been studied and used as therapeutic targets. Simon and Schwacha (33) suggested that MCM2 was a promising target for blocking the proliferation of cancerous and precancerous cells.
In the present study, MMP2 was identified to be essential in causing cervical cancer. MMPs are zinc-containing endopeptidases with an extensive range of substrate specificities. These enzymes are able to degrade various components of extracellular matrix (ECM) proteins. In photocarcinogenesis, degradation of the ECM is the initial step towards tumor cell invasion, to intrude in the basement membrane and the surrounding stroma that primarily comprises fibrillary collagens. Additionally, MMP2 is involved in angiogenesis, which promotes cancer cell growth and migration (34) .
COL1A1 and COL1A2 encode the α1 and α2 chains of type I collagen, respectively (35) . The primary constituents of the ECM are collagens, adhesive glycoproteins and proteoglycans (36) . Specific interactions between cells and ECM-mediated cell-surface-associated components and transmembrane molecules result in the control of cellular activities, including adhesion and migration (37) . Collagen is the primary component of the ECM, which serves pivotal roles in maintaining skin and vessel elasticity, and increasing cartilage lubricity (38) . Upregulation of type II collagen expression may contribute to ovarian cancer metastasis and biological processes, including cell proliferation, invasion and migration (39) . The oncogene JUN is the putative transforming gene of avian sarcoma virus 17, which is the most extensively studied protein of the activator protein-1 complex and is involved in numerous cell activities, including proliferation, apoptosis, survival, tumorigenesis and tissue morphogenesis. The present study identified that COL1A1 was important in ovarian cancer, which was highly connected with cervical and endometrial cancer. Therefore, COL1A1 and JUN may be potentially important associated genes of the three types of gynecological malignancies. miRNAs are small noncoding regulatory RNAs that downregulate transcription by targeting specific mRNAs. Furthermore, the present study identified that certain miRNAs were highly associated with hub connected genes, including let7, which is one of the founding members of the miRNA family. This miRNA was first identified in Caenorhabditis elegans. Lee and Dutta (40) identified six functional let7 target sites in the 3'-untranslated region of high mobility group AT-hook 2 (HMGA2), which reduced HMGA2 expression and cell proliferation in a lung cancer cell line. Using genome-wide mRNA expression analysis, Mi et al (41) identified that miRNA let7B was downregulated in acute lymphoblastic leukemia (ALL) compared with acute myeloid leukemia (AML). Quantitative polymerase chain reaction analysis confirmed the downregulation of let7B in ALL samples compared with AML samples and normal controls.
The present study identified that let7a, let7b and let7c had strong connections with the hub genes and that these miRNAs may serve an important part of the potential mechanism, which may explain the connections across the hub genes.
Overall, the present study identified a number of DEGs associated with gynecological cancer, in addition to the functions and signaling pathways in which these genes were involved. Comprehensive network analyses of the dysregulated gene expression in gynecological cancers identified a series of hub genes and the connection genes across ovarian cancer, cervical cancer and endometrial cancer in a PPI network. Subsequently, this study confirmed the driver genes by survival analysis using the TCGA database. Comprehensive network analyses of miRNAs and connection driver genes identified certain miRNAs which may be potential therapeutic and prevention targets of gynecological cancer. In addition, the present study demonstrated the associations across the different gynecological cancers, which may be useful for identifying potential useful diagnostic markers and novel therapeutic targets. The results of this study may provide an insight into the underlying mechanism of the aforementioned gynecological cancers and may lead to further improvement in diagnosis and treatment of them.
